{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:46:19Z","timestamp":1794271579836,"version":"4.9.0"},"reference-count":232,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jacc.2021.12.011","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:12:55Z","timestamp":1648829575000},"page":"1757-1780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":892,"title":["2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary"],"prefix":"10.1016","volume":"79","author":[{"given":"Paul A.","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni J.","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Colvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Drazner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Dunlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri E.","family":"Fedson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateeti","family":"Khazanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo A.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine C.","family":"Nnacheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne Warner","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.12.011_bib1","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib3","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib4","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020\u00a0ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib6","series-title":"Methodology manual and policies from the ACCF\/AHA Task Force on Practice Guidelines","year":"2010"},{"key":"10.1016\/j.jacc.2021.12.011_bib7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation\u00a0of\u00a0sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib11","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.12.011_bib12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib16","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib18","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","article-title":"Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"20","author":"Woodard-Grice","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2021.12.011_bib20","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib22","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib24","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib26","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib27","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2017.09.011","article-title":"Long-term results of high-intensity exercise-based cardiac rehabilitation in revascularized patients for symptomatic coronary artery disease","volume":"121","author":"Nilsson","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.12.011_bib42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib44","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0000000000001052","article-title":"Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2021.12.011_bib45","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged\u00a0\u226575 years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib46","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib48","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib49","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib50","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib51","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2012.12.022","article-title":"Incremental cost-effectiveness of guideline-directed medical therapies for heart failure","volume":"61","author":"Banka","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000006908","article-title":"The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure","volume":"91","author":"Dasbach","year":"1999","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2021.12.011_bib54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1071-9164(05)80006-5","article-title":"Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial","volume":"1","author":"Glick","year":"1995","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib55","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1994.00420100129016","article-title":"Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure","volume":"154","author":"Paul","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2003.12.040","article-title":"Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"148","author":"Reed","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib57","first-page":"1","article-title":"Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness","author":"Shekelle","year":"2003","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.jacc.2021.12.011_bib58","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0735-1097(95)00284-1","article-title":"Cost-effectiveness of captopril therapy after myocardial infarction","volume":"26","author":"Tsevat","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of Sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib60","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction","volume":"5","author":"Gaziano","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib61","first-page":"392","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib62","first-page":"368","article-title":"Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure","volume":"4","author":"Sandhu","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cardfail.2005.06.433","article-title":"Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial","volume":"11","author":"Caro","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0002-9149(98)01066-2","article-title":"Cost effectiveness of carvedilol for heart failure","volume":"83","author":"Delea","year":"1999","journal-title":"Am J Cardiol"},{"issue":"suppl 7A","key":"10.1016\/j.jacc.2021.12.011_bib65","doi-asserted-by":"crossref","first-page":"74S","DOI":"10.1016\/S0002-9343(98)00387-8","article-title":"Economic impact of beta blockade in heart failure","volume":"110","author":"Gregory","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib66","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1345\/aph.10114","article-title":"Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program","volume":"35","author":"Vera-Llonch","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2021.12.011_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1015371616135","article-title":"Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure","volume":"16","author":"Glick","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2021.12.011_bib68","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/11319940-000000000-00000","article-title":"Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS","volume":"10","author":"Zhang","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2021.12.011_bib70","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1161\/CIRCULATIONAHA.105.563882","article-title":"Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure","volume":"112","author":"Angus","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib71","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-142-8-200504190-00007","article-title":"Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II","volume":"142","author":"Al-Khatib","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib72","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/europace\/eup068","article-title":"Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population","volume":"11","author":"Cowie","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2021.12.011_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/CIRCULATIONAHA.105.581884","article-title":"Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)","volume":"114","author":"Mark","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib74","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/01.CIR.97.21.2129","article-title":"The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial","volume":"97","author":"Mushlin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib75","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMsa051989","article-title":"Cost-effectiveness of implantable cardioverter-defibrillators","volume":"353","author":"Sanders","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib76","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.jacc.2006.03.032","article-title":"The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II","volume":"47","author":"Zwanziger","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib77","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.jacc.2005.08.033","article-title":"Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial","volume":"46","author":"Feldman","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib78","first-page":"204","article-title":"Economic value and cost-effectiveness of cardiac resynchronization therapy among patients with mild heart failure: projections from the REVERSE long-term follow-up","volume":"5","author":"Gold","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00129784-200606020-00007","article-title":"Cost effectiveness of biventricular pacemakers in heart failure patients","volume":"6","author":"Heerey","year":"2006","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2021.12.011_bib80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-141-5-200409070-00102","article-title":"Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure","volume":"141","author":"Nichol","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1540-8167.2012.02413.x","article-title":"Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial","volume":"24","author":"Noyes","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib82","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M14-1804","article-title":"Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure","volume":"163","author":"Woo","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib83","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib84","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2021.12.011_bib85","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCHEARTFAILURE.113.000807","article-title":"Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure","volume":"7","author":"Long","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib86","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib87","first-page":"110","article-title":"Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure","volume":"5","author":"Baras Shreibati","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib88","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/MAT.0000000000001209","article-title":"Cost-effectiveness of thoracotomy approach for the implantation of a centrifugal left ventricular assist device","volume":"66","author":"Mahr","year":"2020","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacc.2021.12.011_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCHEARTFAILURE.111.962951","article-title":"Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy","volume":"5","author":"Rogers","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib90","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MAT.0000000000001211","article-title":"Cost-effectiveness of a small intrapericardial centrifugal left ventricular assist device","volume":"66","author":"Silvestry","year":"2020","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacc.2021.12.011_bib91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ejhf.642","article-title":"Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial","volume":"19","author":"Martinson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib92","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/clc.22696","article-title":"Cost-effectiveness of remote cardiac monitoring with the cardiomems heart failure system","volume":"40","author":"Schmier","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib93","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib94","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib95","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib96","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib97","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jacc.2021.12.011_bib98","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib99","first-page":"472","article-title":"A\u00a0modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2021.12.011_bib100","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2017.1324418","article-title":"Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis","volume":"24","author":"Brown","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2021.12.011_bib102","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib103","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib104","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib105","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cardfail.2015.04.013","article-title":"Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee","volume":"21","author":"Fang","year":"2015","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib107","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/ejhf.1313","article-title":"Advanced heart failure: trans-atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement","volume":"20","author":"Greenberg","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib108","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib109","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/heartjnl-2012-302313","article-title":"Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials","volume":"99","author":"Thomas","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.12.011_bib111","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib112","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib113","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","article-title":"Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group","volume":"278","author":"Kostis","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib114","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0000000000000848","article-title":"Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2021.12.011_bib116","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003613","article-title":"Effect of intensive blood pressure treatment on heart failure events in the Systolic Blood Pressure Reduction Intervention Trial","volume":"10","author":"Upadhya","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib117","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib118","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/hrt.2011.225482","article-title":"Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study","volume":"97","author":"Butler","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.12.011_bib119","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib121","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib122","first-page":"520","article-title":"Contribution of major lifestyle risk factors for incident heart failure in older adults: the Cardiovascular Health Study","volume":"3","author":"Del Gobbo","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib123","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/CIRCHEARTFAILURE.111.962589","article-title":"Lifestyle factors in relation to heart failure among Finnish men and women","volume":"4","author":"Wang","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCHEARTFAILURE.113.000529","article-title":"Effects of physical activity and sedentary time on the risk of heart failure","volume":"7","author":"Young","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.109.887893","article-title":"Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure","volume":"121","author":"Hu","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib126","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjmed.2015.03.027","article-title":"American Heart Association's Life's Simple 7: avoiding heart failure and preserving cardiac structure and function","volume":"128","author":"Folsom","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib127","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ejhf.481","article-title":"Adherence to a Mediterranean diet is associated with reduced risk of heart failure in men","volume":"18","author":"Tektonidis","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib128","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archinternmed.2009.56","article-title":"Consistency with the DASH diet and incidence of heart failure","volume":"169","author":"Levitan","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib129","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjcard.2009.06.061","article-title":"Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years","volume":"104","author":"Levitan","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib130","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2019.01.067","article-title":"Dietary patterns and incident heart failure in U.S. adults without known coronary disease","volume":"73","author":"Lara","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib131","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib132","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib133","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archinte.159.11.1197","article-title":"Profile for estimating risk of heart failure","volume":"159","author":"Kannel","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib134","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/CIRCHEARTFAILURE.108.768457","article-title":"Incident heart failure prediction in the elderly: the health ABC heart failure score","volume":"1","author":"Butler","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib135","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCHEARTFAILURE.111.964841","article-title":"Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"5","author":"Agarwal","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib136","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib137","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib138","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/hrt.2006.112508","article-title":"Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials","volume":"93","author":"Afilalo","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.12.011_bib139","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jacc.2006.08.052","article-title":"N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC\/BHF heart protection study","volume":"49","author":"Emberson","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib140","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/eurheartj\/ehv072","article-title":"The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials","volume":"36","author":"Preiss","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib141","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib142","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.amjcard.2009.01.377","article-title":"Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction","volume":"103","author":"Strandberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib143","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1388-9842(03)00112-0","article-title":"VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context","volume":"5","author":"Velazquez","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib144","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib145","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib146","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0735-1097(96)00489-5","article-title":"Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators","volume":"29","author":"Vantrimpont","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib147","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib148","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2006.10.077","article-title":"A\u00a0randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure","volume":"49","author":"Dargie","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib149","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM198808183190701","article-title":"The effect of diltiazem on mortality and reinfarction after myocardial infarction","volume":"319","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib151","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib152","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib153","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib154","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib155","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib156","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.04.187","article-title":"The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials","volume":"218","author":"Kang","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib157","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjcard.2010.12.020","article-title":"Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure","volume":"107","author":"Banach","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib158","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ahj.2005.03.009","article-title":"The association between blood pressure and mortality in patients with heart failure","volume":"151","author":"Lee","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib159","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib160","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1183\/09031936.00083312","article-title":"Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial","volume":"42","author":"Arzt","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2021.12.011_bib161","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jacc.2017.01.041","article-title":"Cardiovascular outcomes with minute ventilation-targeted adaptive servo-ventilation therapy in heart failure: the CAT-HF trial","volume":"69","author":"O'Connor","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib162","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive servo-ventilation for central sleep apnea in systolic heart failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib163","first-page":"CD012803","article-title":"Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure","volume":"12","author":"Yamamoto","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2021.12.011_bib164","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1161\/CIRCULATIONAHA.106.683482","volume":"115","author":"Arzt","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib165","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.011_bib166","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib167","doi-asserted-by":"crossref","first-page":"603e601","DOI":"10.1016\/j.amjmed.2011.09.030","article-title":"Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation","volume":"125","author":"Mason","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib168","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib169","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib171","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib172","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/eurjhf\/hft111","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial","volume":"15","author":"Ferreira","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib173","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.112.000143","article-title":"Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"6","author":"McMurray","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib174","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2018.04.093","article-title":"Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: the PREFER in AF-HF substudy","volume":"265","author":"Siller-Matula","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib175","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ejhf.595","article-title":"Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48","volume":"18","author":"Magnani","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib176","first-page":"870","article-title":"Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis","volume":"4","author":"Savarese","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib177","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib178","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib179","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1093\/eurheartj\/ehz443","article-title":"Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data","volume":"41","author":"Chen","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib180","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib181","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/01.CIR.101.10.1138","article-title":"Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis","volume":"101","author":"Wood","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib182","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/01.CIR.98.10.953","article-title":"Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study","volume":"98","author":"Brignole","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib183","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1540-8167.2005.50062.x","article-title":"Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study)","volume":"16","author":"Doshi","year":"2005","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib184","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/eurheartj\/ehi069","article-title":"Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation","volume":"26","author":"Brignole","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib185","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/eurheartj\/ehr162","article-title":"Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial","volume":"32","author":"Brignole","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib186","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1093\/eurheartj\/ehy555","article-title":"A\u00a0randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS","volume":"39","author":"Brignole","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib187","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/eurjhf\/hfs036","article-title":"Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode","volume":"14","author":"Chatterjee","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib188","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2017.08.041","article-title":"Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study","volume":"70","author":"Prabhu","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib189","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1161\/CIRCULATIONAHA.106.661397","article-title":"Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HEFT)","volume":"115","author":"Freudenberger","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib190","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib191","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.011_bib192","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.jacc.2017.09.027","article-title":"Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction","volume":"70","author":"Mogensen","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib193","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/01.CIR.91.9.2335","article-title":"Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience","volume":"91","author":"Caracciolo","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib194","first-page":"878","article-title":"CABG improves outcomes in patients with ischemic cardiomyopathy: 10-year follow-up of the STICH Trial","volume":"7","author":"Howlett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.12.011_bib195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.7326\/M13-1380","article-title":"Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial","volume":"161","author":"Mark","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib196","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jacc.2020.07.047","article-title":"Revascularization in patients with left main coronary artery disease and left ventricular dysfunction","volume":"76","author":"Park","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib197","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/CIRCULATIONAHA.116.024800","article-title":"Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure)","volume":"134","author":"Petrie","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib198","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jacc.2020.06.052","article-title":"Long-term survival after surgical or percutaneous revascularization in patients with diabetes and multivessel coronary disease","volume":"76","author":"Tam","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib199","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib200","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.011_bib201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-3029-0","article-title":"Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival","volume":"146","author":"Wang","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jacc.2021.12.011_bib202","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.12.011_bib203","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib204","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib205","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.12.011_bib206","doi-asserted-by":"crossref","first-page":"djv301","DOI":"10.1093\/jnci\/djv301","article-title":"The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study","volume":"108","author":"Goldhar","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2021.12.011_bib207","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2021.12.011_bib208","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","article-title":"Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients","volume":"11","author":"Henry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2021.12.011_bib209","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","article-title":"Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice: a study of the Southeast Netherlands Breast Cancer Consortium","volume":"21","author":"Seferina","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jacc.2021.12.011_bib211","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-019-05178-z","article-title":"Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy","volume":"176","author":"Abu-Khalaf","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jacc.2021.12.011_bib212","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1634\/theoncologist.2015-0449","article-title":"Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment","volume":"21","author":"Truong","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jacc.2021.12.011_bib213","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clbc.2011.07.006","article-title":"Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy","volume":"12","author":"Jeyakumar","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jacc.2021.12.011_bib214","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2014.06.026","article-title":"Utility of prechemotherapy evaluation of left ventricular function for patients with lymphoma","volume":"15","author":"Steuter","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacc.2021.12.011_bib215","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JOP.2012.000682","article-title":"Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Conrad","year":"2012","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jacc.2021.12.011_bib216","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-018-05114-7","article-title":"The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis","volume":"174","author":"O'Brien","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jacc.2021.12.011_bib217","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.12.011_bib218","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib219","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib220","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib221","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib222","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.011_bib223","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib224","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.12.011_bib225","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.amjcard.2019.05.046","article-title":"Meta-analysis comparing usefulness of beta blockers to preserve left ventricular function during anthracycline therapy","volume":"124","author":"Shah","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib226","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised\u00a0trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacc.2021.12.011_bib227","first-page":"54","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jacc.2021.12.011_bib228","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/COC.0000000000000389","article-title":"Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or beta-blockers in older adults with breast cancer","volume":"41","author":"Wittayanukorn","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jacc.2021.12.011_bib229","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.011_bib230","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.12.011_bib231","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.011_bib232","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721083947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721083947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:48:53Z","timestamp":1760017733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721083947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":232,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0735109721083947"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}